← back to search

E. Shelley Hwang

Duke University · US
Area of research
Cancer Research · Pathology and Forensic Medicine
Research interest
Research interests include Breast Cancer Treatment Studies, Breast Lesions and Carcinomas, Breast Implant and Reconstruction, and Global Cancer Incidence and Screening.
h-index
35
citations
8,156
works
162
NIH funding
primary concept
Medicine
email

Recent publications

Survival Disparities in Patients With Metastatic Breast Cancer.
2026cited by 1position: contributordoi
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
2026cited by 0position: contributordoi
Risk Stratification for Sentinel Lymph Node Positivity in Older Women With Early-Stage Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2 Neu-Negative Invasive Breast Cancer.
2025cited by 0position: contributordoi
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
JAMA 2024cited by 64position: firstdoi
Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome
Breast Cancer Research 2024cited by 7position: middledoi
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study
BMJ 2023cited by 42position: middledoi
Transforming the Future of Surgeon-Scientists
Annals of Surgery 2023cited by 19position: lastdoi
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts
Cancer Cell 2022cited by 88position: middledoi
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
Nature Genetics 2022cited by 87position: middledoi
Learning to distinguish progressive and non-progressive ductal carcinoma in situ
Nature reviews. Cancer 2022cited by 48position: middledoi
Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast
Journal of Surgical Oncology 2022cited by 18position: middledoi
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Journal of Clinical Oncology 2021cited by 980position: middledoi
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
2021cited by 688position: contributordoi
Mobile Health Application for Patients Undergoing Breast Cancer Surgery: Feasibility Study.
2021cited by 18position: contributordoi
Outcomes and Costs for Women After Breast Cancer: Preparing for Improved Survivorship of Medicare Beneficiaries.
2021cited by 8position: contributordoi
Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment.
2021cited by 5position: contributordoi
Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression
Nature Materials 2020cited by 306position: middledoi
Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change
Annals of Surgical Oncology 2020cited by 39position: firstdoi
Ductal carcinoma in situ: to treat or not to treat, that is the question
British Journal of Cancer 2019cited by 330position: middledoi
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)
BMJ Open 2019cited by 306position: firstdoi
Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ
Nature Communications 2019cited by 53position: middledoi
Classifying the evolutionary and ecological features of neoplasms
Nature reviews. Cancer 2017cited by 450position: middledoi
Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration
Integrative Biology 2015cited by 1,071position: middledoi
Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells
Cancer Cell 2014cited by 984position: middledoi
Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression
Nature Medicine 2014cited by 417position: middledoi
Survival after lumpectomy and mastectomy for early stage invasive breast cancer
Cancer 2013cited by 258position: firstdoi
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Annals of Surgical Oncology 2013cited by 225position: lastdoi
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer
Cancer 2013cited by 203position: lastdoi
Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27+ Cell Population with Progenitor Characteristics
Cell stem cell 2013cited by 78position: middledoi
Impact of Ductal Carcinoma In Situ Terminology on Patient Treatment Preferences
JAMA Internal Medicine 2013cited by 75position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Esther H. Lips · The Netherlands Cancer Institute4 papers (2012–2023)Jelle Wesseling · Leiden University Medical Center4 papers (2012–2023)Alastair M. Thompson · Baylor School4 papers (2019–2023)Deborah Collyar · Case Western Reserve University3 papers (2019–2023) · 3 papers (2021–2026)Yunn‐Yi Chen · University of California, San Francisco3 papers (2013–2014)Laura J. Esserman · UCSF Helen Diller Family Comprehensive Cancer Center2 papers (2012–2013)Serena Nik‐Zainal · University of Cambridge2 papers (2019–2022) · 2 papers (2019–2024)Aseem Lal · Mount Vernon Hospital2 papers (2013–2013)Sibylle Loibl · Breast Center2 papers (2021–2021) · 2 papers (2019–2022)Mehra Golshan · Yale New Haven Hospital2 papers (2013–2020)Rachel A. Greenup · Duke University2 papers (2013–2022)Celia P. Kaplan · San Francisco General Hospital2 papers (2013–2019)Marjanka K. Schmidt · American Cancer Society2 papers (2022–2023)Frederic M. Waldman · Radiation Oncology Associates2 papers (2013–2013)Irene Acerbi · University of California, San Francisco2 papers (2014–2015)Valerie M. Weaver · University of California, San Francisco2 papers (2014–2015) · 2 papers (2022–2023)